HomeCompareCHMMF vs JNJ

CHMMF vs JNJ: Dividend Comparison 2026

CHMMF yields 200000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHMMF wins by $4.911780474428384e+29M in total portfolio value
10 years
CHMMF
CHMMF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full CHMMF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CHMMF vs JNJ

📍 CHMMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHMMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHMMF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHMMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHMMF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CHMMF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHMMF + JNJ for your $10,000?

CHMMF: 50%JNJ: 50%
100% JNJ50/50100% CHMMF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CHMMF
No analyst data
Altman Z
-32.8
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHMMF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHMMFJNJ
Forward yield200000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.911780474428384e+29M$30.3K
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.911464459982279e+29M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHMMF vs JNJ ($10,000, DRIP)

YearCHMMF PortfolioCHMMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$20,010,700$20,000,000.00$10,592$272.30+$20.00MCHMMF
2$37,424,589,019$37,403,177,570.09$11,289$357.73+$37424.58MCHMMF
3$65,416,215,188,220$65,376,170,877,969.18$12,123$472.89+$65416215.18MCHMMF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$13,141$629.86+$106868230495.00MCHMMF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$14,408$846.81+$163172871735896.88MCHMMF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$16,021$1,151.60+$232854599801468864.00MCHMMF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$18,122$1,588.22+$310570858137017057280.00MCHMMF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$20,930$2,228.20+$3.871481543016132e+23MCHMMF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$24,792$3,191.91+$4.510617497632811e+26MCHMMF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$30,274$4,689.40+$4.911780474428384e+29MCHMMF

CHMMF vs JNJ: Complete Analysis 2026

CHMMFStock

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Full CHMMF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CHMMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHMMF vs SCHDCHMMF vs JEPICHMMF vs OCHMMF vs KOCHMMF vs MAINCHMMF vs ABBVCHMMF vs MRKCHMMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.